Table 1.
Basic data for all included studies in the meta-analysis
| References | Year | Country | Sample size | Cancer-type | Method | Follow-up (months) | Cutoff (high/low) | TNM stage
|
Survival
|
Quality score | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | Method | Outcomes | |||||||||
| Sanfiorenzo et al24 | 2013 | France | 52 | NSCLC | qrt-PCR | 60 | 24/28 | NR | NR | Multivariate | DFS | 8 |
| Heegaard et al15 | 2012 | USA | 180 | NSCLC | qrt-PCR | 60 | 90/90 | NR | NR | Univariate | OS | 8 |
| Wu et al17,* | 2014 | China | 194 | ESCC | qrt-PCR | 60 | 113/81 | 1:3 | 1:5 | Multivariate | OS | 8 |
| 2:48 | 2:62 | |||||||||||
| 3:21 | 3:36 | |||||||||||
| 4:5 | 4:2 | |||||||||||
| Wu et al18 | 2014 | China | 63 | ESCC | qrt-PCR | 24 | NR | NR | NR | Univariate | OS | 8 |
| Komatsu et al19 | 2015 | Japan | 46 | PC | qrt-PCR | 50 | 25/20 | NR | NR | Univariate | CSS | 8 |
| Stamatopoulos et al20 | 2009 | Belgium | 110 | CLL | qrt-PCR | 300 | 37/73 | NR | NR | Univariate | OS, TFS | 8 |
| Zhou et al13 | 2012 | China | 53 | CLL | qrt-PCR | 90 | 31/22 | NR | NR | Univariate | OS, TFS | 8 |
| Dong et al21 | 2016 | China | 112 | OSC | qrt-PCR | 60 | 59/53 | 2a:22 | 2a:50 | Multivariate | OS | 8 |
| 2b/3:40 | 2b/3:10 | |||||||||||
| Wu et al22 | 2014 | China | 94 | NSCLC | qrt-PCR | 48 | 47/47 | 3:23 | 3:29 | Multivariate | OS | 8 |
| 4:24 | 4:18 | |||||||||||
| Qu23 | 2014 | China | 98 | MM | qrt-PCR | 48 | 49/49 | 1+2:22 | 1+2:30# | Univariate | OS, PFS | 8 |
| 3:27 | 3:19 | |||||||||||
Note:
#
ISS, international staging system.
Abbreviations: NSCLC, nonsmall cell lung carcinoma; ESCC, esophageal squamous cell carcinoma; PC, pancreatic cancer; CLL, chronic lymphocytic leukemia; OSC, osteosarcoma; OS, overall survival; MM, multiple myeloma; TNM, tumor node metastasis; qrt-PCR, quantitative real-time PCR; DFS, disease-free survival; TFS, treatment-free survival; CSS, cause-specific survival; PFS, progression-free survival; NR, not reported.